Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease

  • Christian Gratzke
  • Karl-Erik Andersson
  • Thorsten Diemer
  • Wolfgang Weidner
  • Christian G. Stief
Part of the Springer Specialist Surgery Series book series (SPECIALIST)


Erectile dysfunction (ED) is defined as persistent inability to attain and/or maintain an erection sufficient for sexual performance.1,2 It is assumed that 5–20% of men complain of moderate to severe ED3; common risk factors are very similar to risk factors of cardiovascular disease and include smoking, hypertension, diabetes, lipidemia, atherosclerosis, and pelvic surgery.2,4 The introduction of oral drugs has revolutionized the medical treatment of ED; successful intercourse can be achieved with inhibitors of phosphodiesterase 5 (PDE-5) such as sildenafil, tadalafil, and vardenafil in about 75% of patients suffering from ED.5 However, a considerable amount of men does not respond to PDE-5 inhibitors, particularly patients with diabetes mellitus (DM) or patients having undergone radical prostatectomy. This chapter aims to present a pragmatic approach for the clinical diagnosis and therapy of ED, based on available literature, particularly the guidelines of the European Association of Urology,6 the American Urological Association7 as well as the British Society for Sexual Medicine,5 and on current research and clinical practice.


Erectile Dysfunction Radical Prostatectomy Lower Urinary Tract Symptom PDE5 Inhibitor Erectile Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-450PubMedGoogle Scholar
  2. 2.
    Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813PubMedCrossRefGoogle Scholar
  3. 3.
    Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res. 2003;15(1):63-71PubMedCrossRefGoogle Scholar
  4. 4.
    Roumeguere T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol. 2003;44(3):355-359PubMedCrossRefGoogle Scholar
  5. 5.
    Hackett G, Kell P, Ralph D, et al. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5(8):1841-1865PubMedCrossRefGoogle Scholar
  6. 6.
    Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol. 2006;49(5):806-815PubMedCrossRefGoogle Scholar
  7. 7.
    Montague DK, Jarow J, Broderick GA, et al. American urological association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318-1324PubMedCrossRefGoogle Scholar
  8. 8.
    Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002;168(2):615-620PubMedCrossRefGoogle Scholar
  9. 9.
    Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178(2):597-601PubMedCrossRefGoogle Scholar
  10. 10.
    Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1(1):6-23PubMedCrossRefGoogle Scholar
  11. 11.
    Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. J Am Med Assoc. 2004;292 (12):1440-1446CrossRefGoogle Scholar
  12. 12.
    Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology. 1995;45(3):498-502PubMedCrossRefGoogle Scholar
  13. 13.
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-830PubMedCrossRefGoogle Scholar
  14. 14.
    Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med. 2004;1(1):49-57PubMedCrossRefGoogle Scholar
  15. 15.
    Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463PubMedCrossRefGoogle Scholar
  16. 16.
    Montorsi P, Ravagnani PM, Galli S, et al. Common grounds for erectile dysfunction and coronary artery disease. Curr Opin Urol. 2004;14(6):361-365PubMedCrossRefGoogle Scholar
  17. 17.
    Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(12B):85M–93MPubMedCrossRefGoogle Scholar
  18. 18.
    Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement – update 2002 Int J Clin Pract. 2002;56(9):663-671PubMedGoogle Scholar
  19. 19.
    Meuleman EJ, Diemont WL. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Urol Clin North Am. 1995;22(4):803-819PubMedGoogle Scholar
  20. 20.
    Jarow JP, DeFranzo AJ. Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease. J Urol. 1996;156(3):982-985PubMedCrossRefGoogle Scholar
  21. 21.
    Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006;50(6):1194-1207; discussion 1207PubMedCrossRefGoogle Scholar
  22. 22.
    Dula E, Bukofzer S, Perdok R, George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39(5):558-553; discussion 564PubMedCrossRefGoogle Scholar
  23. 23.
    Andersson KE, Stief C. Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. World J Urol. 2001;19(1):9-13PubMedCrossRefGoogle Scholar
  24. 24.
    Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The alprostadil study group. N Engl J Med. 1996;334(14):873-877PubMedCrossRefGoogle Scholar
  25. 25.
    Jaffe JS, Antell MR, Greenstein M, Ginsberg PC, Mydlo JH, Harkaway RC. Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology. 2004;63(5):951-954PubMedCrossRefGoogle Scholar
  26. 26.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1-7PubMedCrossRefGoogle Scholar
  27. 27.
    Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie’s disease: a review. J Urol. 2003;169(4):1234-1241PubMedCrossRefGoogle Scholar
  28. 28.
    Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: Results of a large survey. BJU Int. 2001;88(7):727-730PubMedCrossRefGoogle Scholar
  29. 29.
    Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol. 1990;144(6):1376-1379PubMedGoogle Scholar
  30. 30.
    Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie’s disease: a critical analysis. Eur Urol. 2006;50(2):235-248PubMedCrossRefGoogle Scholar
  31. 31.
    Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R. Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol. 1997;157(1):325-328PubMedCrossRefGoogle Scholar
  32. 32.
    Hauck EW, Hauptmann A, Weidner W, Bein G, Hackstein H. Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie’s disease. J Urol. 2003;170(4 Pt 1):1443-1446PubMedCrossRefGoogle Scholar
  33. 33.
    Haag SM, Hauck EW, Szardening-Kirchner C, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol. 2007;51(1):255-261PubMedCrossRefGoogle Scholar
  34. 34.
    Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie’s disease. Eur Urol. 2006;49(6):987-997PubMedCrossRefGoogle Scholar
  35. 35.
    Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: A prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-535; discussion 535-536PubMedCrossRefGoogle Scholar
  36. 36.
    Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol. 2004;171(4):1605-1608PubMedCrossRefGoogle Scholar
  37. 37.
    Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171(2 Pt 1):740-745PubMedCrossRefGoogle Scholar
  38. 38.
    Hauck EW. Against the motion: surgery is the best choice for Peyronie’s disease. Eur Urol. 2006;49(6):1128; discussion 1128-1129PubMedCrossRefGoogle Scholar
  39. 39.
    Lue TF, El-Sakka AI. Venous patch graft for Peyronie’s disease part I: technique. J Urol. 1998;160(6 Pt 1): 2047-2049PubMedGoogle Scholar
  40. 40.
    El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie’s disease part II: outcome analysis. J Urol. 1998;160(6 Pt 1):2050-2053PubMedCrossRefGoogle Scholar
  41. 41.
    Hellstrom WJ, Reddy S. Application of pericardial graft in the surgical management of Peyronie’s disease. J Urol. 2000;163(5):1445-1447PubMedCrossRefGoogle Scholar
  42. 42.
    Hauck EW, Weidner W. Francois de la Peyronie and the disease named after him. Lancet. 2001;357(9273):2049-2051PubMedCrossRefGoogle Scholar
  43. 43.
    Montorsi F, Salonia A, Maga T, et al. Reconfiguration of the severely fibrotic penis with a penile implant. J Urol. 2001;166(5):1782-1786PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Christian Gratzke
    • 1
  • Karl-Erik Andersson
    • 2
  • Thorsten Diemer
    • 3
  • Wolfgang Weidner
    • 4
  • Christian G. Stief
    • 1
  1. 1.Department of UrologyUniversity-Hospital Grosshadern, Ludwig-Maximilians-University MunichMunichGermany
  2. 2.Institute for Regenerative MedicineWake Forest University Medical SchoolWinston SalemUSA
  3. 3.Department of UrologyUniversity-Hospital Giessen and Marburg GmbH, Justus-Liebig-University GiessenGiessenGermany
  4. 4.Department of Urology, Pediatric Urology and AndrologyUniversity Hospital Giessen and Marburg GmbHGiessenGermany

Personalised recommendations